ClinicalTrials.gg

Program

Human Growth Hormone

Also written as “somatropin”, “Somatropin” and “PEG-somatropin”.

Its studies are mostly in Dwarfism, Pituitary · Turner Syndrome · Dwarfism · Growth Disorders · Genetic Diseases, Inborn, led by 15 companies.

Furthest: phase 4, since Sep 13, 2005117 company-led studies, 5 open or runningNext primary completion: Apr 28, 2027 (phase 4)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Novo Nordisk340 open or runningphase 4since Sep 13, 2005Feb 1, 2005none ahead
Changchun GeneScience Pharmaceutical194 open or runningphase 4since Nov 27, 2014Apr 21, 2011Apr 28, 2027phase 4 · NCT07691125
Merck KGaA, Darmstadt, Germany190 open or runningphase 4since Nov 18, 2005May 13, 2004none ahead
Pfizer180 open or runningphase 4since Feb 5, 2007Sep 9, 2005none ahead
Eli Lilly100 open or runningphase 4since Dec 15, 2005Sep 12, 2005none ahead
LG Chem40 open or runningphase 4since Nov 10, 2016Dec 29, 2005none ahead
Daewoong Pharmaceutical20 open or runningphase 3since Jan 19, 2016Sep 23, 2011none ahead
Ferring Pharmaceuticals20 open or runningphase 3since Nov 7, 2005Nov 7, 2005none ahead
Hoffmann-La Roche20 open or runningphase 4since Dec 4, 2014Mar 11, 2004none ahead
Ipsen20 open or runningphase 4since Aug 24, 2011Oct 5, 2005none ahead
altus-pharmaceuticals10 open or runningphase 2since Feb 2, 2009Feb 2, 2009none ahead
Azidus Brasil10 open or runningphase 1since Nov 28, 2011Nov 28, 2011none ahead
Clinique Ovo10 open or runningphase 4since Oct 24, 2012Oct 24, 2012none ahead
Sanofi10 open or runningphase 3since Mar 23, 2007Mar 23, 2007none ahead
zhongshan-sansure-hygene-biomedicine-co-ltd11 open or runningphase 3since Sep 2, 2026Sep 2, 2026Oct 2028phase 3 · NCT07815626

Also a collaborator on its studies: Merck Serono S.A.S, France, Merck Serono Co., Ltd., China, Merck Serono S.P.A., Italy, Merck Serono S.A., Geneva, Merck, S.L., Spain and BioPartners.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 45 studies since Dec 16, 2009.

  1. Mar 28, 2017Phase 2 study in Dwarfism, PituitaryChangchun GeneScience Pharmaceutical · NCT03104010 · 180 enrolled · China
  2. Jul 14, 20172 phase 2 studies in DwarfismChangchun GeneScience Pharmaceutical · NCT03255694, NCT03221088
  3. Jul 18, 2017Phase 3 study in Small for Gestational Age InfantChangchun GeneScience Pharmaceutical · NCT03245333 · 120 enrolled · China
  4. Jul 24, 2017Phase 4 study in Dwarfism, PituitaryChangchun GeneScience Pharmaceutical · NCT03249480 · 900 enrolled · China
  5. Sep 19, 2017Phase 4 study in Growth RetardationChangchun GeneScience Pharmaceutical · NCT03290235 · 1,500 enrolled · China
  6. Apr 28, 2018Phase 3 study in DwarfismChangchun GeneScience Pharmaceutical · NCT03535415 · 68 enrolled · China
  7. May 30, 2018Phase 3 study in Prader-Willi SyndromeChangchun GeneScience Pharmaceutical · NCT03554031 · 30 enrolled · China
  8. Dec 21, 2018Phase 3 study in Dwarfism, PituitaryPfizer · NCT03831880 · 87 enrolled · United States, Bulgaria, Czechia and more
  9. Sep 9, 2019Phase 1 study in Bioavailability, Safety and Tolerability Among Different Eutropin Formulations in Healthy VolunteersLG Chem · NCT04085224 · 24 enrolled · Korea, Republic of
  10. Apr 25, 2022Phase 4 study in AchondroplasiaChangchun GeneScience Pharmaceutical · NCT05353192 · 39 enrolled · China
  11. Aug 9, 2023Phase 3 study in Dwarfism, PituitaryChangchun GeneScience Pharmaceutical · NCT06024967 · 180 planned
  12. Apr 14, 2026Phase 1 study in HealthyPfizer · NCT07542886 · 27 enrolled · Belgium
  13. Jul 1, 2026Phase 4 study in Short Bowel SyndromeChangchun GeneScience Pharmaceutical · NCT07691125 · 100 planned · China
  14. Sep 2, 2026zhongshan-sansure-hygene-biomedicine-co-ltd's first study: phase 3 study in Idiopathic Short Stature (ISS)New to zhongshan-sansure-hygene-biomedicine-co-ltdzhongshan-sansure-hygene-biomedicine-co-ltd · NCT07815626 · 240 planned · China

Ahead

  1. Apr 28, 2027Primary completion: phase 4 study in Short Bowel SyndromeChangchun GeneScience Pharmaceutical · NCT07691125
  2. Oct 2028Primary completion: phase 3 study in Idiopathic Short Stature (ISS)zhongshan-sansure-hygene-biomedicine-co-ltd · NCT07815626
  3. Jun 2030Primary completion: phase 2 study in DwarfismChangchun GeneScience Pharmaceutical · NCT03255694

TargetBeta

GHR →read by rule
“Growth hormone receptor agonist”ChEMBL 37, by rule

Other programs on GHR

ProgramCompanyFurthest phaseStudies
lonapegsomatropinruleascendis-pharma-endocrinology-division-a-sphase 36

Studies

The newest 60 of 117 led by companies developing it. Each opens its study page. Every study on its drug page →

StudyPhaseStatusLed byPrimary completionSize
NCT07815626Idiopathic Short Stature (ISS) · China3Not yet recruitingzhongshan-sansure-hygene-biomedicine-co-ltdOct 2028240
NCT07691125Short Bowel Syndrome · China4RecruitingChangchun GeneScience PharmaceuticalApr 28, 2027100
NCT07542886Healthy · Belgium1CompletedPfizerJun 25, 202627
NCT06024967Dwarfism, Pituitary3Not yet recruitingChangchun GeneScience PharmaceuticalMay 1, 2025180
NCT05353192Achondroplasia · China4CompletedChangchun GeneScience PharmaceuticalAug 25, 202539
NCT04085224Bioavailability, Safety and Tolerability Among Different Eutropin Formulations in Healthy Volunteers · Korea, Republic of1CompletedLG ChemJan 2, 202024
NCT03831880Dwarfism, Pituitary · United States, Bulgaria, Czechia and more3CompletedPfizerAug 28, 202087
NCT03554031Prader-Willi Syndrome · China3UNKNOWNChangchun GeneScience PharmaceuticalJan 202030
NCT03535415Dwarfism · China3UNKNOWNChangchun GeneScience PharmaceuticalSep 202068
NCT03290235Growth Retardation · China4UNKNOWNChangchun GeneScience PharmaceuticalOct 20201,500
NCT03249480Dwarfism, Pituitary · China4UNKNOWNChangchun GeneScience PharmaceuticalAug 2017900
NCT03245333Small for Gestational Age Infant · China3UNKNOWNChangchun GeneScience PharmaceuticalDec 2017120
NCT03255694Dwarfism · China2Active, not recruitingChangchun GeneScience PharmaceuticalJun 2030360
NCT03221088Dwarfism · China2UNKNOWNChangchun GeneScience PharmaceuticalDec 2018360
NCT03104010Dwarfism, Pituitary · China2UNKNOWNChangchun GeneScience PharmaceuticalFeb 2022180
NCT02976675Dwarfism, Pituitary · China4UNKNOWNChangchun GeneScience PharmaceuticalJun 2017600
NCT03015909Dwarfism · Korea, Republic of4CompletedLG ChemDec 21, 2017116
NCT02908958Dwarfism, Pituitary · China4UNKNOWNChangchun GeneScience PharmaceuticalJun 2017900
NCT02693522Dwarfism, Pituitary · Korea, Republic of3CompletedDaewoong PharmaceuticalDec 200452
NCT02380235Dwarfism, Pituitary · China4UNKNOWNChangchun GeneScience PharmaceuticalJun 2017600
NCT02375620Short Stature Children Born Small for Gestational Age (SGA) · China2Active, not recruitingChangchun GeneScience PharmaceuticalDec 12, 202396
NCT02311894Dwarfism, Pituitary · United States4CompletedHoffmann-La RocheNov 8, 201782
NCT02314676Dwarfism, Pituitary · China4UNKNOWNChangchun GeneScience PharmaceuticalJul 2017900
NCT01927861Genetic Diseases, Inborn · Japan3CompletedNovo NordiskJul 12, 201851
NCT01859949Dwarfism · Japan4CompletedPfizerAug 201562
NCT01806298Dwarfism, Pituitary · Australia, Germany, Sweden and more4CompletedMerck KGaA, Darmstadt, GermanyMar 201678
NCT01778023Growth Disorders · Korea, Republic of3CompletedNovo NordiskDec 17, 201454
NCT01746862Idiopathic Short Stature · Korea, Republic of3CompletedMerck KGaA, Darmstadt, GermanyAug 201490
NCT01734486Genetic Diseases, Inborn · France4CompletedNovo NordiskMay 21, 200331
NCT01734447Foetal Growth Problem · France4CompletedNovo NordiskApr 30, 200357
NCT01715324Infertility · Canada4CompletedClinique OvoJul 2021288
NCT01698944Dwarfism, Pituitary · Greece4TerminatedNovo NordiskNov 18, 20027
NCT01697644Foetal Growth Problem · Netherlands4CompletedNovo NordiskMay 200575
NCT01613573Dwarfism, Pituitary1CompletedChangchun GeneScience PharmaceuticalOct 201012
NCT01563926Genetic Diseases, Inborn · Israel3CompletedNovo NordiskOct 10, 2002168
NCT01562834Dwarfism, Pituitary · France4CompletedNovo NordiskDec 1, 200222
NCT01518062Genetic Diseases, Inborn · Netherlands4CompletedNovo NordiskSep 200365
NCT01518036Genetic Diseases, Inborn · United Kingdom3CompletedNovo NordiskApr 11, 200457
NCT01512095Growth Disorders1WithdrawnNovo NordiskNov 20130
NCT01529944Genetic Diseases, Inborn · Sweden3CompletedNovo NordiskOct 200822
NCT01529840Genetic Diseases, Inborn · Sweden3CompletedNovo NordiskSep 200524
NCT01502137Renal Insufficiency, Chronic · Germany1CompletedNovo NordiskNov 200521
NCT01502124Growth Hormone Disorder · United States3CompletedNovo NordiskMar 5, 200378
NCT01495468Dwarfism, Pituitary · China3CompletedChangchun GeneScience PharmaceuticalJan 2008343
NCT01494779Dwarfism, Pituitary · Brazil1UNKNOWNAzidus BrasilJun 201332
NCT01440686Dwarfism, Pituitary · Korea, Republic of1CompletedDaewoong PharmaceuticalDec 201140
NCT01438801Idiopathic Short Stature4WithdrawnIpsenMay 31, 20130
NCT01400698Children Born With Serious Intra-uterine Growth Retardation3CompletedMerck KGaA, Darmstadt, GermanyFeb 201091
NCT01401244Genetic Diseases, Inborn · United States1CompletedNovo NordiskSep 27, 201130
NCT01342146Dwarfism, Pituitary2CompletedChangchun GeneScience PharmaceuticalJan 2007101
NCT01237340Dwarfism, Pituitary · United States3TerminatedMerck KGaA, Darmstadt, GermanyDec 201159
NCT01187550Dwarfism, Pituitary4CompletedMerck KGaA, Darmstadt, GermanySep 2008214
NCT01157793Dwarfism4CompletedMerck KGaA, Darmstadt, GermanyFeb 200534
NCT01111019Hypochondroplasia · France2CompletedMerck KGaA, Darmstadt, GermanyJan 17, 201719
NCT01077960Human Immunodeficiency Virus-Associated Adipose Redistribution Syndrome · United States, Canada3CompletedMerck KGaA, Darmstadt, GermanyJan 2006126
NCT01073605Growth Disorders · France3CompletedPfizerMay 2009208
NCT01067352Infant, Small for Gestational Age · Italy3TerminatedMerck KGaA, Darmstadt, GermanyJul 200925
NCT01066052Turner Syndrome · France4CompletedMerck KGaA, Darmstadt, GermanyMar 31, 1999115
NCT01034735Failure to Thrive · Germany1CompletedMerck KGaA, Darmstadt, GermanyAug 200830
NCT01034202Growth Hormone Disorder · Denmark1CompletedNovo NordiskJan 200856

How it is read

Names in the registry

  • “somatropin”, 52 entries
  • “Somatropin”, 27 entries
  • “PEG-somatropin”, 13 entries
  • “Saizen®”, 6 entries
  • “Genotropin”, 5 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.